Identification

Name
Metocurine Iodide
Accession Number
DB00416  (APRD01318)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. Metocurine Iodide is no longer available on the US market.

Structure
Thumb
Synonyms
  • (+)-O,O'-Dimethylchondrocurarine Di-iodide
  • Dimethyl Tubocurarine Iodide
  • Dimethyltubocurarine Iodide
  • Dimethyltubocurarinium iodide
  • Dimetiltubocurarinio, ioduro de
  • Metocurine iodide
  • Metocurini Iodidum
  • Metokuriinijodidi
  • Metokurinjodid
  • Trimethyltubocurarine Iodide
External IDs
NSC-36388
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Metubine Iodide Inj 2mg/mlLiquid2 mgIntravenousEli Lilly & Co. Ltd.1948-12-311998-08-04Canada
International/Other Brands
Metubine iodide
Categories
UNII
O0U0E87X7F
CAS number
7601-55-0
Weight
Average: 906.6279
Monoisotopic: 906.160174118
Chemical Formula
C40H48I2N2O6
InChI Key
DIGFQJFCDPKEPF-OIUSMDOTSA-L
InChI
InChI=1S/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1
IUPAC Name
(1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁸,²².0²⁷,³¹.0¹⁶,³⁴]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaene-15,30-diium diiodide
SMILES
[I-].[I-].[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CC[N+]1(C)C)C2=C6)=C(OC)C=C5)=CC(OC)=C4OC)C=C3

Pharmacology

Indication

For use as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.

Pharmacodynamics

Metocurine iodide is a benzylisoquinolinium competitive nondepolarizing neuromuscular blocking agent. Metocurine iodide has a moderate risk of inducing histamine release and has some ganglion blocking activity. Metocurine iodide can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of metocurine iodide. Repeated administration of maintenance doses of metocurine iodide has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.

Mechanism of action

Metocurine iodide antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

35% in plasma

Metabolism
Not Available
Route of elimination
Not Available
Half life

3 to 4 hours

Clearance
Not Available
Toxicity

Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinMetocurine Iodide may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinMetocurine Iodide may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineAgmatine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental, Investigational
AmikacinThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneAmiodarone may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
ApramycinApramycin may increase the respiratory depressant activities of Metocurine Iodide.Experimental, Vet Approved
AranidipineAranidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
ArbekacinArbekacin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Investigational
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Metocurine Iodide.Approved, Vet Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
AzosemideAzosemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
Beclomethasone dipropionateThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Metocurine Iodide.Experimental
BencyclaneBencyclane may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
BenidipineBenidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Metocurine Iodide.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Metocurine Iodide.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Metocurine Iodide.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
BioallethrinBioallethrin may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
Botulinum Toxin Type BMetocurine Iodide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Metocurine Iodide.Approved
BudesonideThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Metocurine Iodide.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Metocurine Iodide.Approved, Investigational
CarboxyamidotriazoleCarboxyamidotriazole may increase the neuromuscular blocking activities of Metocurine Iodide.Investigational
CaroverineCaroverine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Metocurine Iodide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Metocurine Iodide.Approved
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Metocurine Iodide.Approved, Investigational
ClevidipineClevidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
ClindamycinThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Clindamycin.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Metocurine Iodide.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Vet Approved
CyclandelateCyclandelate may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metocurine Iodide.Approved
CyclosporineThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CymarinMetocurine Iodide may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineDarodipine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
DeslanosideMetocurine Iodide may increase the arrhythmogenic activities of Deslanoside.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Desvenlafaxine.Approved, Investigational
DexamethasoneThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metocurine Iodide.Approved
DexniguldipineDexniguldipine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
DextromethorphanThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Dextromethorphan.Approved
DexverapamilDexverapamil may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
DibekacinDibekacin may increase the respiratory depressant activities of Metocurine Iodide.Experimental
DigitoxinMetocurine Iodide may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinMetocurine Iodide may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Metocurine Iodide may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Metocurine Iodide.Investigational, Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Metocurine Iodide.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metocurine Iodide.Approved, Investigational
DotarizineDotarizine may increase the neuromuscular blocking activities of Metocurine Iodide.Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Metocurine Iodide.Approved, Vet Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
EmopamilEmopamil may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
EperisoneEperisone may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
EthanolMetocurine Iodide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideEthosuximide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Metocurine Iodide.Approved
FelodipineFelodipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metocurine Iodide.Approved, Illicit, Investigational, Vet Approved
Fish oilFish oil may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Nutraceutical
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Fluoxetine.Approved, Vet Approved
FluspirileneFluspirilene may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Metocurine Iodide.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Fluvoxamine.Approved, Investigational
FramycetinFramycetin may increase the respiratory depressant activities of Metocurine Iodide.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
GallopamilGallopamil may increase the neuromuscular blocking activities of Metocurine Iodide.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Metocurine Iodide.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Metocurine Iodide.Experimental
GitoformateMetocurine Iodide may increase the arrhythmogenic activities of Gitoformate.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Metocurine Iodide.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Metocurine Iodide.Approved, Vet Approved
HydrocodoneMetocurine Iodide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metocurine Iodide.Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Metocurine Iodide.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Metocurine Iodide.Approved
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Metocurine Iodide.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Metocurine Iodide.Experimental
IsradipineIsradipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Investigational, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Metocurine Iodide.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
Lanatoside CMetocurine Iodide may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
LevetiracetamLevetiracetam may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Metocurine Iodide.Approved
LidoflazineLidoflazine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
LincomycinLincomycin may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Vet Approved
Lithium cationLithium may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
LomerizineLomerizine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
LoperamideLoperamide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Metocurine Iodide.Approved, Investigational
Magnesium carbonateThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Magnesium citrate.Approved
Magnesium hydroxideThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
Magnesium sulfateThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Magnesium Trisilicate.Approved
ManidipineManidipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Metocurine Iodide.Approved
MentholMenthol may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
MethsuximideMethsuximide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
MethyclothiazideMethyclothiazide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved
MethylprednisoloneThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetocurine Iodide may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetoclopramideThe therapeutic efficacy of Metocurine Iodide can be decreased when used in combination with Metoclopramide.Approved, Investigational
MibefradilMibefradil may increase the neuromuscular blocking activities of Metocurine Iodide.Investigational, Withdrawn
MicronomicinMicronomicin may increase the respiratory depressant activities of Metocurine Iodide.Experimental
MinocyclineMinocycline may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Metocurine Iodide.Investigational
NeamineNeamine may increase the respiratory depressant activities of Metocurine Iodide.Experimental
NeomycinThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Neomycin.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Investigational
NicardipineNicardipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
NifedipineNifedipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
NimesulideNimesulide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
NylidrinNylidrin may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
OleandrinMetocurine Iodide may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Metocurine Iodide.Approved
OtiloniumOtilonium may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental, Investigational
OuabainMetocurine Iodide may increase the arrhythmogenic activities of Ouabain.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metocurine Iodide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metocurine Iodide.Approved, Investigational, Vet Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational, Vet Approved
ParomomycinThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Paroxetine.Approved, Investigational
PenfluridolPenfluridol may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
PeruvosideMetocurine Iodide may increase the arrhythmogenic activities of Peruvoside.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metocurine Iodide.Approved, Investigational
PinaveriumPinaverium may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Metocurine Iodide.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Investigational
Polymyxin B SulfateThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Polymyxin B Sulfate.Approved, Vet Approved
PramipexoleMetocurine Iodide may increase the sedative activities of Pramipexole.Approved, Investigational
PrednisoloneThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Prednisolone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metocurine Iodide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Metocurine Iodide.Approved, Investigational
ProscillaridinMetocurine Iodide may increase the arrhythmogenic activities of Proscillaridin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Pseudoephedrine.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Metocurine Iodide.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metocurine Iodide.Approved
QuinethazoneQuinethazone may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Rizatriptan.Approved
RopiniroleMetocurine Iodide may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Metocurine Iodide.Approved, Investigational
SeletracetamSeletracetam may increase the neuromuscular blocking activities of Metocurine Iodide.Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Metocurine Iodide.Investigational
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Vet Approved
SumatriptanThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Sumatriptan.Approved, Investigational
TerodilineTerodiline may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
TetracyclineThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Tetracycline.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the neuromuscular blocking activities of Metocurine Iodide.Investigational
TetrandrineTetrandrine may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
TobramycinTobramycin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Metocurine Iodide.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metocurine Iodide.Approved, Investigational
TranilastTranilast may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Vet Approved
TrimebutineTrimebutine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
TrimethadioneTrimethadione may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Metocurine Iodide.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Metocurine Iodide.Approved, Investigational
VancomycinThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Metocurine Iodide.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Metocurine Iodide.Investigational
WIN 55212-2WIN 55212-2 may increase the neuromuscular blocking activities of Metocurine Iodide.Experimental
ZiconotideZiconotide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Metocurine Iodide is combined with Zolmitriptan.Approved, Investigational
ZolpidemMetocurine Iodide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Bray, M.D.; U.S. Patent 2,581,903; January 8, 1952; assigned to Eli Lilly and Company.

General References
Not Available
External Links
Human Metabolome Database
HMDB0014560
KEGG Drug
D00761
PubChem Compound
24244
PubChem Substance
46507773
ChemSpider
22666
ChEBI
6901
ChEMBL
CHEMBL1739
Therapeutic Targets Database
DAP000824
PharmGKB
PA164749507
Wikipedia
Metocurine_Iodide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Eli lilly and co
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntravenous2 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)267-270Bray, M.D.; U.S. Patent 2,581,903; January 8, 1952; assigned to Eli Lilly and Company.
Predicted Properties
PropertyValueSource
Water Solubility0.000123 mg/mLALOGPS
logP0.81ALOGPS
logP-1.8ChemAxon
logS-6.9ALOGPS
pKa (Strongest Acidic)12.99ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area55.38 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity211.94 m3·mol-1ChemAxon
Polarizability73.46 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9112
Blood Brain Barrier+0.9374
Caco-2 permeable+0.6898
P-glycoprotein substrateSubstrate0.8261
P-glycoprotein inhibitor INon-inhibitor0.6293
P-glycoprotein inhibitor IINon-inhibitor0.7474
Renal organic cation transporterNon-inhibitor0.5766
CYP450 2C9 substrateNon-substrate0.826
CYP450 2D6 substrateNon-substrate0.6251
CYP450 3A4 substrateSubstrate0.6945
CYP450 1A2 substrateNon-inhibitor0.8688
CYP450 2C9 inhibitorNon-inhibitor0.9391
CYP450 2D6 inhibitorNon-inhibitor0.8916
CYP450 2C19 inhibitorNon-inhibitor0.8992
CYP450 3A4 inhibitorNon-inhibitor0.8879
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9634
Ames testAMES toxic0.5764
CarcinogenicityNon-carcinogens0.8865
BiodegradationNot ready biodegradable0.9867
Rat acute toxicity2.7013 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8502
hERG inhibition (predictor II)Non-inhibitor0.6006
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Diarylethers
Alternative Parents
Tetrahydroisoquinolines / Anisoles / Aralkylamines / Alkyl aryl ethers / Tetraalkylammonium salts / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organic zwitterions / Organic iodide salts
show 1 more
Substituents
Diaryl ether / Tetrahydroisoquinoline / Anisole / Alkyl aryl ether / Aralkylamine / Benzenoid / Tetraalkylammonium salt / Quaternary ammonium salt / Oxacycle / Azacycle
show 10 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Liu M, Dilger JP: Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. [PubMed:18633030]
  4. Iwatsuki N, Hashimoto Y, Amaha K, Obara S, Iwatsuki K: Inotropic effects of non-depolarizing muscle relaxants in isolated canine heart muscle. Anesth Analg. 1980 Oct;59(10):717-21. [PubMed:6107062]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:20